ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022
Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2024Pooled it
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Reduced visceral adipose tissue area linked to early recurrence in HCC patients with HBV: a parallel mediation analysis.Abdominal radiology (New York) · 2026Article
- Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.Journal of cachexia, sarcopenia and muscle · 2026Article
- Prevalence of Malnutrition, Frailty, and Cachexia Across Different Cancer Subtypes: Distribution by Age (<65 and ≥65).Journal of clinical medicine · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.Frontiers in nutrition · 2026Article
- Cancer cachexia-related monocytic myeloid-derived suppressor cells impair T-cell negative selection and predict immune-related adverse events.Liver research (Beijing, China) · 2025Article
- Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance.Hepatology communications · 2025Review
- Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.World journal of clinical oncology · 2025Article
- Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape.World journal of gastroenterology · 2025Article
- Predicting the Occurrence of Cachexia in Patients with BCLC Stage B/C Hepatocellular Carcinoma Receiving Systemic Therapy: A Nomogram Based on Common Clinical Parameters.Journal of hepatocellular carcinoma · 2025Article
- Optoacoustic imaging of the brain in a cachexia-inducing pancreatic cancer xenograft.Frontiers in oncology · 2025Article
- Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China.Clinical and molecular hepatology · 2025Article
- Prognostic utility of the global leadership initiative on malnutrition criteria in predicting outcomes after hepatectomy for hepatocellular carcinoma: a multicenter, retrospective study.Frontiers in nutrition · 2025Article
- Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213).Journal of cachexia, sarcopenia and muscle · 2024Article
- Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predicts Cachexia and Prognosis in Hepatocellular Carcinoma Patients.Current medical science · 2024Article
- The prognostic impact of perioperative dynamic changes in cachexia index in patients with hepatocellular carcinoma.Annals of gastroenterological surgery · 2024Article
- Anabolic deficits and divergent unfolded protein response underlie skeletal and cardiac muscle growth impairments in the Yoshida hepatoma tumor model of cancer cachexia.Physiological reports · 2024Article
- Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma.World journal of hepatology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsCancer cachexia is a wasting syndrome associated with functional impairment and reduced survival that impacts up to 50% of patients with gastrointestinal cancers. However, data are limited on the prevalence and clinical significance of cachexia in patients with hepatocellular carcinoma (HCC).
methodsWe performed a retrospective cohort study of patients diagnosed with HCC at 2 United States health systems between 2008 and 2018. Patient weights were recorded 6 months prior to and at time of HCC diagnosis. Cachexia was defined as >5% weight loss (or >2% weight loss if body mass index <20 kg/m
resultsOf 604 patients with HCC, 201 (33.3%) had precachexia and 143 (23.7%) had cachexia at diagnosis, including 19.0%, 23.5%, 34.7%, and 34.0% of patients with Barcelona Clinic Liver Cancer stages 0/A, B, C, and D, respectively. Patients with cachexia were less likely to receive HCC treatment (odds ratio, 0.38; 95% confidence interval, 0.21-0.71) and had worse survival than those with precachexia or stable weight (11.3 vs 20.4 vs 23.5 months, respectively; P < .001). Cachexia remained independently associated with worse survival (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84) after adjusting for age, sex, race, ethnicity, Child Pugh class, alpha-fetoprotein, Barcelona Clinic Liver Cancer stage, and HCC treatment.
conclusionsNearly 1 in 4 patients with HCC present with cachexia, including many with compensated cirrhosis or early stage tumors. The presence of cancer-associated weight loss appears to be an early and independent predictor of worse outcomes in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.